GBT
DNTH icon

Grove Bank & Trust’s Dianthus Therapeutics DNTH Stock Holding History

Grove Bank & Trust’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95K Buy
61
+2
+3% +$175 ﹤0.01% 711
2026
Q1 		$4.95K Buy
+59
New +$3.42K ﹤0.01% 709

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Grove Bank & Trust's DNTH Position: Q2 2026 in Review

Grove Bank & Trust increased its Dianthus Therapeutics (DNTH) stake by 3.4% in Q2 2026, buying an estimated $175 and bringing the position to 61 shares worth $5.95K. The position accounts for ﹤0.01% of the portfolio, ranked #711.

Grove Bank & Trust first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Grove Bank & Trust held 61 shares of Dianthus Therapeutics worth $5.95K as of Q2 2026.
  • Grove Bank & Trust bought 2 Dianthus Therapeutics shares in Q2 2026, an estimated $175.
  • Dianthus Therapeutics made up ﹤0.01% of Grove Bank & Trust's portfolio in Q2 2026, its #711 holding.
  • Grove Bank & Trust first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.